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To characterize glucagon-like peptide (GLP)-1 signaling and its
effect on renal endothelial dysfunction and glomerulopathy. We
studied the expression and signaling of GLP-1 receptor (GLP-1R)
on glomerular endothelial cells and the novel ﬁnding of protein
kinase A–dependent phosphorylation of c-Raf at Ser259 and its
inhibition of angiotensin II (Ang II) phospho–c-Raf(Ser338) and
Erk1/2 phosphorylation. Mice overexpressing protein kinase
C (PKC)b2 in endothelial cells (EC-PKCb2Tg) were established.
Ang II and GLP-1 actions in glomerular endothelial cells were
analyzed with small interfering RNA of GLP-1R. PKCb isoform
activation induced by diabetes decreased GLP-1R expression and
protective action on the renal endothelium by increasing its deg-
radation via ubiquitination and enhancing phospho–c-Raf(Ser338)
and Ang II activation of phospho-Erk1/2. EC-PKCb2Tg mice
exhibited decreased GLP-1R expression and increased phospho–
c-Raf(Ser338), leading to enhanced effects of Ang II. Diabetic
EC-PKCb2Tg mice exhibited greater loss of endothelial GLP-1R
expression and exendin-4–protective actions and exhibited more
albuminuria and mesangial expansion than diabetic controls.
These results showed that the renal protective effects of GLP-1
were mediated via the inhibition of Ang II actions on cRaf
(Ser259) and diminished by diabetes because of PKCb activation
and the increased degradation of GLP-1R in the glomerular endo-
thelial cells. Diabetes 61:2967–2979, 2012
E
ndothelial pathologies such as thrombotic micro-
angiopathy and mesangiolysis are parts of glo-
merulopathy because of insulin resistance and
diabetes, which are leading causes of clinical re-
nal disease (1,2). Endothelial dysfunction is postulated to
accelerate the progression of diabetic glomerulopathy as
a result of the inhibition of endothelial nitric oxide (NO)
synthesis (eNOS) and its product, NO (3).
We have reported that activation of the b isoform of
protein kinase C (PKC) by hyperglycemia can cause glo-
merular endothelial dysfunction and reduce eNOS activation
partially owing to inhibition of insulin action on glomerular
endothelial cells (4,5). Clinically, ruboxistaurin (RBX),
a speciﬁc inhibitor of PKCb, has been reported to improve
endothelial dysfunction induced by hyperglycemia (4,6).
Further, studies have associated PKCb activation with
glomerular pathology induced by hyperglycemia possibly
due to the enhancement of angiotensin action (7). However,
the biochemical mechanism by which PKCb enhances an-
giotensin II (Ang II) action to accelerate the progression of
diabetic glomerulopathy has not been clariﬁed.
Recently, glucagon-like peptide-1 (GLP-1) has been re-
ported to biologically improve endothelial function and
prevent some renal pathologies in diabetic rodents (8,9).
However, a mechanistic explanation regarding GLP-1–
protective action on the endothelial cell is unknown.
GLP-1 is a gut incretin hormone that augments glucose-
dependent insulin responses in the b cells (10). GLP-1
receptor (GLP-1R) is present abundantly in the gastroin-
testinal tract but has also been reported in endothelium
and kidney and may stimulate NO production (8,11,12). In
this study, we have identiﬁed a new biochemical mecha-
nism for GLP-1 to inhibit Ang II inﬂammatory action via the
c-Raf/extracellular signal–related kinase (Erk)1/2/plasminogen
activator inhibitor (PAI)-1 pathway in glomerular endothe-
lial cells. Further, we have demonstrated a dual signaling
mechanism by which diabetes, via PKCb activation, can in-
crease Ang II action by increasing the inﬂammatory cytokines
and extracellular matrix and inhibiting GLP-1–protective
effects by reducing GLP-1R expression in the glomerular
endothelium.
RESEARCH DESIGN AND METHODS
Generation of endothelial cell–speciﬁc PKCb2–overexpressing mice. All
animal protocols were approved by the Joslin Diabetes Center committee in
accordance with NIH guidelines. The pVECD-PKCb2 vector was constructed
by inserting mouse PKCb2 cDNA into pVECD vector (13). Transgenic mice
expressing PKCb2 were generated from C57BL/6J mice. Diabetes was induced
by ﬁve consecutive days of injections of streptozotocin (STZ) (55 mg/kg
body wt; Sigma) in 0.05 mol/L citrate buffer (pH 4.5). Blood glucose levels
were determined by glucose analyzer (Yellow Spring Instruments). Glycemic
levels .16.7mmol/L were deﬁned as having diabetes. Two weeks after di-
abetes, exendin-4 (1.0 nmol/kg/day; Sigma) or diluents were administrated
intraperitoneally to mice for 6 months. Regular human insulin (10 mU/g; Lilly)
or diluents were injected into the inferior vena cava for 10 min to study insulin
signaling. Kidneys were harvestedand procedures were performedwithin 30 min.
Measurement of blood pressure. Blood pressure was determined in con-
scious animals using a noninvasive computerized automated tail-cuff system
(Vistech Systems). After the mice were trained for ﬁve consecutive days,
they were placed on a heated platform and studied for three 10-cycle
measurements.
Measurement of urinary albumin, creatinine, and cAMP. Urinary albumin
was measured from 24-h urine collection with mice housed in individual
metabolic cages and assessed by Albuwell (Exocell). Creatinine levels were
measured by colorimetric detection kit (Assay Designs), and urinary cAMP was
measured after injection with exendin-4 or vehicle by using ELISA kit (Cell
Biolab).
Isolation of glomeruli and cell culture. Isolation of mouse glomeruli was
performed as previously described (14). Rat glomerular and lung endothelial
cell were also cultured as previously described (4).
Immunoblot analysis. Samples were dissolved in 0.5% Nonidet P-40 and
immunoprecipitated with antibody to GLP-1R (Santa Cruz Biotechnology) and
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ORIGINAL ARTICLEprotein A/G-Sepharose beads. The proteins were separated by SDS-PAGE and
subsequently blotted with antibodies as indicated.
Immunohistochemistry and real-time PCR analysis. Immunohistochem-
istry and its analysis were performed as previously described (4). Real-time
PCR was also performed as previously described (4) (Supplementary Table 1).
Data analysis. Data are expressed as means 6 SD. Comparisons were made
between groups using either two-sample and paired t tests for two-way
comparisons or one-way ANOVA for multiple groups to establish statistically
signiﬁcant differences. All analyses were performed using StatView (SAS In-
stitute). Statistical signiﬁcance was deﬁned as P , 0.05.
RESULTS
Effect of diabetes and PKCb2 activation on GLP-1R
expression. Double immunostaining studies showed that
GLP-1R was mainly expressed by glomerular endothelial
cells and that expression levels were decreased by 43 6
12% in diabetic mice compared with nondiabetic mice (Fig.
1A). Immunoblot study of renal cortex lysate showed that
GLP-1R protein expression was decreased by 35 6 9%
after 6 months of diabetes (Fig. 1B). In the glomeruli, GLP-
1R protein expression was decreased by 37 6 7% (Sup-
plementary Fig. 1) after 3 months of diabetes. In contrast,
GLP-1R mRNA expression was not changed by diabetes
(Fig. 1C). To evaluate the mechanisms of insulin receptor
substrate 1 diabetes-inhibitory actions, we studied the ef-
fect of PKC activation on GLP-1R expression in glomerular
endothelial cells (RGECs). PKC activation by phorbol
12-myristate 13-acetate (PMA) decreased protein expression
of GLP-1R by 46 6 4% (Fig. 1D) without altering GLP-1R
mRNA levels (Fig. 1E). Addition of GF109203X (GFX),
a general PKC inhibitor, and RBX reversed the inhibitory
effect of PMA by 29 6 8a n d1 76 7%, respectively. Since
diabetes and PKC activation appear to affect GLP-1R by a
posttranscriptional mechanism, the addition of proteasome
inhibitor MG132 in RGECs increased GLP-1R protein levels
by 29 6 10% during PMA treatment (Fig. 1D). To conﬁrm
that increases in the degradation of GLP-1R were induced
by PKC activation, RGECs were exposed to 100 nmol/L
PMA for 4 h, which increased the ubiquitinated GLP-1R
levels signiﬁcantly by 8.9 6 1.1-fold; levels were inhibited by
GFX or RBX by 37 6 6a n d2 26 6%, respectively (Fig. 1F).
Adenovirus-mediated overexpression of PKCb2( A d -
PKCb2) in RGECs decreased GLP-1R protein levels by 29 6
3% compared with a control construct (Fig. 1G) without
changing mRNA expression (Fig. 1H). Overexpression of
PKCa and PKCd isoforms by infection with Ad-PKCa and
Ad-PKCd did not decrease GLP-1R protein expression
(Fig. 1G).
To determine whether PKCb2 activation in the endo-
thelial cells can decrease the expression of GLP-1R, we
created mice overexpressing mouse PKCb2 in endothelial
cells (EC-PKCb2Tg) using a transgene consisting of
a fragment of the vascular endothelial-cadherin promoter
and mouse PKCb2 cDNA (Supplementary Fig. 2A).
Transgenic founder lines carrying the mouse PKCb2
transgene were identiﬁed by Southern blot analysis (Sup-
plementary Fig. 2B). In situ PKC activity increased by 53 6
16% in the glomeruli of EC-PKCb2Tg mice (Supplementary
Fig. 2C). RT-PCR analysis for PKCb2 revealed that mRNA
expression of the transgene in the glomeruli increased by
32 6 8-fold compared with wild-type (WT) mice (Sup-
plementary Fig. 2D). Immunoblot analyses showed that
expression of PKCb2 in cytosolic and membrane frac-
tions from glomeruli increased by 2.8 6 0.3- and 7.5 6 0.3-
fold, respectively, in EC-PKCb2Tg compared with WT
controls (Supplementary Fig. 2E). In contrast, the levels of
PKCa, PKCd, and PKC´ were not changed in cytosolic or
membrane fractions in the renal cortex of transgenic mice
(Supplementary Fig. 2F). Immunoblot analyses of primary
lung endothelial cells showed that the expression of PKCb
increased by 2.6 6 0.9-fold greater in transgenic than in
WT mice (Supplementary Fig. 2G). Double immunostain-
ing of the renal glomeruli showed that the increases of
PKCb2 were detected mainly in the glomerular endothelial
cells (Supplementary Fig. 2H).
GLP-1R expression in the renal glomeruli, measured by
immunohistochemistry, was reduced by 45 6 19% in the
EC-PKCb2Tg mice versus WT mice. After 6 months of di-
abetes, GLP-1R expression in diabetic EC-PKCb2Tg mice
was reduced by 64 6 19% compared with nondiabetic WT
mice and by 37 6 14% versus diabetic WT mice (Fig. 2A).
Immunoblot analysis showed that GLP-1R protein ex-
pression decreased in nondiabetic and diabetic EC-
PKCb2Tg mice by 35 6 4 and 51 6 3%, respectively,
compared with nondiabetic WT mice and reduced by 22 6
3% when diabetic EC-PKCb2Tg mice were compared with
diabetic WT mice (Fig. 2B). GLP-1R protein expression
also decreased in glomeruli of nondiabetic and diabetic
EC-PKCb2Tg mice by 34 6 7 and 59 6 6%, respectively,
compared with nondiabetic WT mice and reduced by 34 6
10% when diabetic EC-PKCb2Tg mice were compared with
diabetic WT mice (Supplementary Fig. 2I). No changes in
GLP-1R mRNA expression levels were observed in any
group (Fig. 2C). The levels of polyubiquitination of GLP-1R
were increased signiﬁcantly in diabetic WT mice by 6.5 6
1.4-fold and in nondiabetic EC-PKCb2Tg mice by 5.3 6 1.1-
fold compared with nondiabetic WT mice. Further, poly-
ubiquitination of GLP-1R in diabetic EC-PKCb2Tg mice
was more prominent by 8.4 6 1.0-fold versus nondiabetic
WT mice and by 1.3 6 0.1-fold compared with nondiabetic
EC-PKCb2Tg mice (Fig. 2D).
Nuclear factor-kB activation and inﬂammation in
renal cortex. We also characterized the effect of PKCb2
activation on nuclear factor-kB (NF-kB) and inﬂammatory
cytokine expression, which are markers of diabetic glo-
merulopathy and angiotensin activation (15,16). NF-kB
activation was observed to be 1.3 6 0.3-fold higher in the
renal cortex of EC-PKCb2Tg mice than in diabetic WT
mice after 6 months of diabetes (Supplementary Fig. 3A).
Similarly, NF-kB, as measured by DNA binding, increased
in both diabetic EC-PKCb2Tg and WT mice compared with
their nondiabetic controls after 3 and 6 months of diabetes
(by 1.3 6 0.1-fold in WT and by 1.5 6 0.2-fold in EC-
PKCb2Tg mice, respectively) (Supplementary Fig. 3B). For
inﬂammatory cytokines, expression of tumor necrosis
factor-a mRNA levels was increased by 3.2 6 1.1- and
1.4 6 0.2-fold after 3 and 6 months of diabetes in diabetic
versus nondiabetic WT mice. After 6 months of diabetes,
tumor necrosis factor-a mRNA levels were 1.4 6 0.2-fold
higher in EC-PKCb2Tg mice compared with WT mice (Sup-
plementary Fig. 3C). Similarly, expression of interleukin-6
mRNA levels in the renal cortex of diabetic WT mice was
increased by 2.9 6 0.6- and 2.0 6 0.5-fold after 3 and
6 months of diabetes compared with WT mice. For EC-
PKCb2Tg mice, diabetes increased interleukin-6 mRNA ex-
pression by 1.5 6 0.5-fold compared with diabetic WT mice
after 6 months of diabetes (Supplementary Fig. 3D). Diabetes
also increased the expression of CD68 mRNA levels in WT
mice by 6.1 6 2.9-fold and in EC-PKCb2Tg mice by 6.1 6
2.8-fold at 3 months (Supplementary Fig. 3E).
Effect of diabetes on renal function and pathology.
After 6 months, body weight, blood glucose, and plasma
insulin concentrations were not different between diabetic
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2968 DIABETES, VOL. 61, NOVEMBER 2012 diabetes.diabetesjournals.orgFIG. 1. Diabetes and PKCb2 activation decreases GLP-1R. A: Immunostaining for GLP-1R and CD31 and merge images in the glomeruli and
morphometric analysis of glomerular expression of GLP-1R and CD31. For quantiﬁcation of the expression of GLP-1R and CD31, the positive
staining area/glomerular area (%) was measured using ImageJ (NIH). For each animal, 50 glomeruli were evaluated. Bar = 50 mm. n = 6 in non-
diabetic WT and diabetic WT mice; n = 7 in nondiabetic transgenic and diabetic transgenic mice. n = number of mice. DM, mice with STZ-induced
diabetes; NDM, nondiabetic mice. *P < 0.05. Magniﬁcation 3400. B: Immunoblots of GLP-1R from renal cortex of mice with STZ-induced diabetes
for 6 months. n = 6 in nondiabetic WT and diabetic WT mice; n = 7 in nondiabetic transgenic and diabetic transgenic mice. *P < 0.05. C: GLP-1R
mRNA expression in the renal cortex of mice with STZ-induced diabetes for 6 months. n = 6 in nondiabetic WT and diabetic WT mice; n =7i n
nondiabetic transgenic and diabetic transgenic mice. D: Immunoblots of GLP-1R in RGECs. RGECs were incubated with PMA (4 h) with or without
a PKC-speciﬁc inhibitor (GFX), PKCb-speciﬁc inhibitor (RBX), or proteasome inhibitor (MG132). **P < 0.001 vs. PMA
2, GFX
2, RBX
2, and
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PKCb2Tg and WT mice (Table 1 and Supplementary Table
2). Diabetic EC-PKCb2Tg mice exhibited more albumin-
uria compared with diabetic WT mice by 1.5 6 0.5-fold
(Fig. 3A), but they did not differ in creatinine clearance
and glomerular ﬁltration rates (Supplementary Figs. 3F
and G). The width of glomerular basement membrane
(GBM) was signiﬁcantly increased by 1.3 6 0.4-fold in di-
abetic EC-PKCb2Tg mice compared with diabetic WT litter-
mates of the same age (Fig. 3B). Mesangial matrix expansion
was 1.4 6 0.4-fold greater in diabetic EC-PKCb2Tg mice
than in diabetic WT mice. Diabetic EC-PKCb2Tg mice also
exhibited a greater fraction of glomerular area stained
for type IV collagen (Col4) and ﬁbronectin than diabetic
WT mice (1.3 6 0.3- and 1.8 6 0.5-fold higher, respectively)
(Fig. 3C). Protein expression of Co14 and ﬁbronectin in
the renal cortex were increased signiﬁcantly in both
groups of diabetic mice, but the increases were much
greater in diabetic EC-PKCb2 T gm i c eb y1 . 46 0.1-fold
compared with diabetic WT mice (Supplementary Fig.
3H). This was also reﬂected in their mRNA levels (Sup-
plementary Fig. I).
Evaluation of PAI-1, tissue plasminogen activator,
and eNOS activation in EC-PKCb2Tg mice. In immu-
nohistochemistry studies, diabetes increased PAI-1–positive
areas in the glomeruli of diabetic EC-PKCb2Tg mice by
1.3 6 0.4-fold more than in diabetic WT mice (17) (Fig. 3D).
Expression of PAI-1 mRNA level was also increased in the
renal cortex of both diabetic WT mice and EC-PKCb2Tg
mice in concordance with histological studies (Supple-
mentary Fig. 3J). In contrast, areas positive for tissue
plasminogen activator and its mRNA did not change in EC-
PKCb2Tg or WT mice compared with nondiabetic controls
(Supplementary Figs. 3K and J).
Analysis of eNOS expression and activation in the renal
cortex showed that insulin increased both phospho-Akt
and phospho-eNOS signiﬁcantly in WT mice, but its effect
was decreased in EC-PKCb2Tg mice compared with WT
mice by 63 6 8 and by 72 6 7%, respectively (P , 0.05)
(Supplementary Fig. 3L) (3).
Effect of exendin-4 in diabetic EC-PKCb2Tg mice. To
determine whether GLP-1 can prevent endothelial dys-
function induced by diabetes, we determined the effect of
treatment with exendin-4, an analog of GLP-1. Infusion
with exendin-4 signiﬁcantly increased urinary cAMP in
nondiabetic WT mice by 1.9 6 0.6-fold, which was de-
creased by 29 6 13% in diabetic WT mice and by 28 6 12%
in nondiabetic EC-PKCb2Tg mice. Exendin-4 did not sig-
niﬁcantly increase urinary cAMP in diabetic EC-PKCb2Tg
mice (Fig. 4A). Treatment with exendin-4 did not prevent
the reduction of GLP-1R protein (Supplementary Fig. 4A)
or mRNA levels (Supplementary Fig. 4B) in the renal cortex
or affect body weight, blood glucose, blood pressure, urine
volume, food intake, plasma insulin, or creatinine clearance
(Supplementary Table 2 and Supplementary Fig. 4C). In
contrast, exendin-4 signiﬁcantly decreased albuminuria in
both diabetic WT and EC-PKCb2Tg mice by 27 6 10 and
44 6 20%, respectively (Fig. 4B). Quantitative analysis of
immunohistochemistry showed that exendin-4 treatment
reduced mesangial matrix fraction in both diabetic WT and
EC-PKCb2Tg mice by 38 6 10 and 31 6 8%, respectively
(Fig. 4C and Supplementary Fig. 4D). Col4- and ﬁbronectin-
positive staining areas were reduced by exendin-4 treat-
ment (Col4 by 26 6 8% in diabetic WT mice and 27 6 9% in
diabetic EC-PKCb2Tg mice and ﬁbronectin by 26 6 11% in
diabetic WT mice and 29 6 13% in diabetic EC-PKCb2T g
mice, respectively) (Supplementary Fig. 4D). Similar
reductions in the mRNA were observed when EC-PKCb2Tg
mice were treated with exendin-4 (Supplementary Fig. 5A).
Immunostaining analysis showed that exendin-4 de-
creased diabetes-induced elevation of PAI-1 protein ex-
pression in diabetic WT and EC-PKCb2Tg mice (by 32 6 11
and 31 6 10%, respectively) (Fig. 4D and Supplementary
Fig. 5B). Expression of PAI-1 mRNA in renal cortex was
decreased by exendin-4 treatment both in diabetic WT and
EC-PKCb2Tg mice by 24 6 9a n d3 26 10%, respectively
(Supplementary Fig. 5C).
Exendin-4 decreased mRNA expression of macrophage
markers CD68 and CXCL2 in diabetic WT (CD68 by 52 6 7
and 31 6 10%, respectively) (Supplementary Fig. 5D) and
EC-PKCb2Tg (CXCL2 by 36 6 11 and 35 6 14%, re-
spectively) mice (Supplementary Fig. 5D and E) (9).
Exendin-4–mediated inhibition of c-Raf/Erk1/2/PAI-1
pathway by angiotensin II. Activation of c-Raf–Erk1/2
pathways by Ang II can mediate the expression of renal
inﬂammatory cytokines (18–20). In RGECs, Ang II signiﬁ-
cantly increased phospho–c-Raf(Ser338), phospho-Erk1/2,
and PAI-1 expression by 9.9 6 2.4-, 9.2 6 2.2-, and 2.2 6
0.6-fold, respectively. Exendin-4 increased phospho–c-Raf
(Ser259) signiﬁcantly by 13 6 1-fold and decreased Ang II
effects on phospho–c-Raf(Ser338), phospho-Erk1/2, and
PAI-1 by 37 6 2, 52 6 6, and 22 6 2%, respectively. H89,
a selective protein kinase A inhibitor, decreased the effect
of exendin-4 on phospho–c-Raf(Ser259) by 43 6 5% and
reduced exendin-4–inhibitory effects on Ang II-induced
phospho–c-Raf(Ser338), phospho-Erk1/2, and PAI-1 by
38 6 4, 35 6 3, and 11 6 2%, respectively. mitogen-
activated protein kinase kinase inhibitor PD98059 de-
creased Ang II action on phospho-Erk1/2 and PAI-1 by
85 6 22 and 38 6 4%, respectively, yet it did not affect
Ang II action on phospho–c-Raf(Ser338), but p38 mitogen-
activated protein kinase inhibitor SB203580 did not have
any effect on these markers (Fig. 5A and Supplemen-
tary Fig. 6A). However, MDL12330A, a cAMP-selective
inhibitor in RGECs, reduced exendin-4–induced phos-
pho–c-Raf(Ser259) by 68 6 7% (Fig. 5B) and partially
reduced exendin-4–inhibitory effects on Ang II action
[phospho–c-Raf(Ser338), phospho-Erk1/2, and PAI-1 by
23 6 7, 45 6 14, and 29 6 9%, respectively] (Fig. 5B and
Supplementary Fig. 6B). These results strongly suggest
that GLP-1–protective action on endothelial cells is
due to cAMP-induced phosphorylation of c-Raf(Ser259),
which inhibits Ang II activation of phospho–c-Raf
(Ser338).
MG132
2. †P < 0.05 vs. PMA
+, GFX
2,R B X
2, and MG132
2. E: GLP-1R mRNA expression in the renal cortex of mice with STZ-induced diabetes for 6
months. F: Immunoprecipitation and immunoblots of ubiquitin-targeted GLP-1R. RGECs were incubated with PMA (4 h) with or without GFX or
RBX. Whole-cell lysates were immunoprecipitated with anti–GLP-1R antibody, subjected to SDS-PAGE, and blotted with ubiquitin antibody. **P <
0.001 vs. PMA
2, GFX
2, and RBX
2. †P < 0.05 vs. PMA
+, GFX
2, and RBX
2. G and H: Immunoblot analyses (G) and mRNA expression (H) of GLP-1R.
RGECs were transfected with Ad–green ﬂuorescent protein (GFP), Ad-PKCa, Ad-PKCb2, or Ad-PKCd as indicated. *P < 0.05 vs. Ad–green
ﬂuorescent protein. One of three independently performed experiments is shown. Comparisons were made between groups using either two-
sample and paired t tests for two-way comparisons or one-way ANOVA for multiple groups to establish statistically signiﬁcant differences. Results
are means 6 SD. AU, arbitrary units; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IB, immunoblot; IP, immunoprecipitation; NS, not
signiﬁcant. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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2970 DIABETES, VOL. 61, NOVEMBER 2012 diabetes.diabetesjournals.orgFIG. 2. Decreases of GLP-1R in the glomeruli of EC-PKCb2Tg mice. A: Immunostaining for GLP-1R and CD31, merge images in the glomeruli, and
morphometric analysis of glomerular expression of GLP-1R and CD31. Bar = 50 mm. DM, mice with STZ-induced diabetes; NDM, nondiabetic mice;
Tg, EC-PKCb2Tg mice. n = 6 in nondiabetic WT and diabetic WT mice; n = 7 in nondiabetic transgenic and diabetic transgenic mice. *P < 0.05 vs.
nondiabetic WT mice. †P < 0.05 vs. diabetic WT mice. Magniﬁcation 3400. B: Immunoblots of GLP-1R from renal cortex of mice with STZ-induced
diabetes for 6 months. n = 6 in nondiabetic WT and diabetic WT mice; n = 7 in nondiabetic transgenic and diabetic transgenic mice. *P < 0.05 vs.
nondiabetic WT mice. †P < 0.05 vs. diabetic WT mice. C: GLP-1R mRNA expression in the renal cortex of mice with STZ-induced diabetes for 6
months. n = 6 in nondiabetic WT and diabetic WT mice; n = 7 in nondiabetic transgenic and diabetic transgenic mice. D: Immunoprecipitation and
immunoblots of ubiquitin-targeted GLP-1R in each group of mice. n = 6 in nondiabetic WT and diabetic WT mice; n = 7 in nondiabetic transgenic and
diabetic transgenic mice. **P < 0.001 vs. nondiabetic WT mice. Results are expressed as means 6 SD. One of three independently performed
experiments is shown. Comparisons were made between groups using either two-sample and paired t tests for two-way comparisons or one-way
ANOVA for multiple groups to establish statistically signiﬁcant differences. AU, arbitrary units; NS, not signiﬁcant; IP, immunoprecipitation; IB,
immunoblot. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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protein kinase, and PAI-1 activity. PKC activation by
PMA increased phospho–c-Raf(Ser338) and phospho-Erk1/2
in RGECs by 2.7 6 0.7- and 7.0 6 3.3-fold, respectively,
but did not alter phospho–c-Raf(Ser259). In contrast, the
addition of exendin-4 increased phospho–c-Raf(Ser259) by
8.9 6 1.0-fold in parallel with decreasing PMA-induced
phospho–c-Raf(Ser338) and phospho-Erk1/2 by 58 6 8 and
43 6 5%, respectively (Fig. 6A). Addition of GFX or RBX
decreased PMA-induced phospho–c-Raf(Ser338) by 55 6 4
and 34 6 4% and phospho-Erk1/2 by 53 6 2 and 31 6 8%,
respectively (Fig. 6B). Similar to PMA, Ang II also in-
creased phospho–c-Raf(Ser338) and phospho-Erk1/2 by
6.0 6 2.1- and 10 6 2-fold, respectively, which were re-
duced signiﬁcantly by inhibitors GFX and RBX by 43 6 2
and 26 6 7%, respectively (Fig. 6C). Lastly, Ang II in-
creased mRNA levels of PAI-1 by 5.4 6 2.4-fold, which was
also inhibited by GFX and RBX by 45 6 21 and 36 6 15%,
respectively (Supplementary Fig. 6C).
Role of GLP-1R on exendin-4 and Ang II signaling. For
ascertainment of whether GLP-1R was mediating exendin-
4–inhibitory effect, the expression of GLP-1R was reduced
by GLP-1R small interfering RNA in RGECs. The addition
of GLP-1R small interfering RNA in RGECs reduced its
expression by 55 6 22% (Supplementary Fig. 6D), inhibited
exendin-4–induced phospho–c-Raf(Ser259) by 47 6 8%
(Fig. 6D), and decreased exendin-4–inhibitory effects on
Ang II signaling of phospho–c-Raf(Ser338), phospho-Erk1/2,
and PAI-1 mRNA by 47 6 6, 16 6 5, and 18 6 3%, re-
spectively (Fig. 6D and Supplementary Fig. 6E and F). Ang
II induced production of PAI-1 by 2.3 6 0.4-fold; production
was decreased by exendin-4. In contrast, knockdown of
GLP-1R in RGECs reduced exendin-4–inhibitory effects by
23 6 5% (Supplementary Fig. 6G). Lastly, blocking GLP-1R
with exendin-3, a GLP-1R antagonist, inhibited exendin-4–
induced phospho–c-Raf(Ser259) by 57 6 4% and increased
phospho–c-Raf(Ser338) and phospho-Erk1/2 by 35 6 3a n d
56 6 2%, respectively (Fig. 6E and Supplementary Fig. 6H)
in the presence of Ang II and exendin-4.
Evaluation of Ang II and effect of GLP-1 on c-Raf in
the glomeruli. Intravenous infusing of Ang II (100 ng/kg/
min) increased phospho–c-Raf(Ser338) and phospho-Erk1/2
by 8.1 6 0.8- and 6.8 6 0.6-fold, respectively, in the
glomeruli of WT mice compared with saline infusion.
Further, Ang II increased phospho-Erk1/2 signiﬁcantly
more in the EC-PKCb2Tg mice than WT mice by 1.4 6 0.2-
fold. In both WT and EC-PKCb2Tg mice, treatment with
exendin-4 increased phospho–c-Raf(Ser259) by 8.6 6
0.2- and 8.8 6 1.0-fold, respectively, and decreased Ang
II-induced phospho–c-Raf(Ser338) by 41 6 11% in WT mice
and by 31 6 9% in EC-PKCb2Tg mice (Fig. 7A).
Similar to the results in the glomeruli, infusing Ang II
increased phospho–c-Raf(Ser338) (by 6.4 6 0.2-fold),
phospho-Erk1/2 (by 7.9 6 3.1-fold), and PAI-1 mRNA (by
11 6 2-fold) levels in the renal cortex compared with levels
in the renal cortex of WT mice without Ang II. Further, Ang
II increased phospho–c-Raf(Ser338), phospho-Erk1/2, and
PAI-1 expression signiﬁcantly more in the EC-PKCb2Tg
mice compared with WT mice with Ang II (by 1.3 6 0.1-,
1.4 6 0.1-, and 1.5 6 0.2-fold, respectively) (Supplementary
Fig. 7A and B). In both WT and EC-PKCb2Tg mice, treat-
ment with exendin-4 increased phospho–c-Raf(Ser259)
and signiﬁcantly decreased Ang II–induced phospho–c-Raf
(Ser338), phospho-Erk1/2, and PAI-1 expression (Supple-
mentary Fig. 7A and B).
As previously reported (4,21), diabetes increased phospho-
Erk1/2 in the renal cortex of both WT and EC-PKCb2Tg
mice, and this increase was 1.8 6 0.3-fold greater in di-
abetic EC-PKCb2Tg mice than diabetic WT mice. Diabetes
also increased phospho–c-Raf(Ser338) in the renal cortex
of diabetic EC-PKCb2Tg mice, and this increase was 1.4 6
0.1-fold greater than the increase in diabetic WT mice.
Lastly, exendin-4 treatment decreased diabetes-induced
increases of phospho-Erk1/2 by 37 6 10% and phospho–
c-Raf(Ser338) by 25 6 3% in WT mice and by 20 6 9 and
16 6 4% in EC-PKCb2Tg mice (Fig. 7B).
DISCUSSION
The current study provides a biochemical pathway by
which GLP-1 mediates its protective action in the glo-
merular endothelial cells to inhibit Ang II signaling and its
proinﬂammatory action. These data demonstrate that hy-
perglycemia via the activation of PKCb can cause endo-
thelial dysfunction through a dual pathway including
reduction of GLP-1R and enhancement of Ang II signaling
and action.
Previously, GLP-1R activation by exendin-4 was shown
to inhibit Ang II activation in renal proximal tubular cells
(22). Our results demonstrate that GLP-1 is partly medi-
ating its protective action via its own receptor by the ac-
tivation of PKA. The elevation of cAMP levels increased
phospho–c-Raf(Ser259), which may inhibit phospho–c-Raf
(Ser338)/phospho-Erk1/2, which are activated by Ang II to
induce its inﬂammatory action such as PAI-1 expression.
Several studies have shown that phosphorylation of c-Raf
(Ser259) induced by cAMP can inhibit the action of
phospho–c-Raf(Ser338), leading to inﬂammatory action
(23,24). The inhibitory effect of cAMP is likely to be direct,
since Dhillon et al. (24) and others have reported a direct
interaction between PKA and c-Raf (25–26). We have
shown for the ﬁrst time in vivo that GLP-1 only in-
creased Ser259 phosphorylation and Ang II–increasing
Ser338 phosphorylation on c-Raf in renal glomeruli.
However, when the two were infused together, GLP-1
clearly decreased Ang II–induced phospho–c-Raf(Ser338).
TABLE 1
Physiological characteristics of nondiabetic and diabetic WT and EC-PKCb2Tg mice
Nondiabetic WT Diabetic WT Nondiabetic Tg Diabetic Tg
n 667 7
Body weight (g) 33.5 6 1.3 25.2 6 1.4* 31.9 6 1.3 23.5 6 3.0*
Blood glucose (mg/dL) 109 6 8 510 6 54* 101 6 7 507 6 57*
SBP (mmHg) 99.9 6 7.8 102.8 6 8.0 101.6 6 10 103.4 6 8.5
rKW/BW (mg/g) 5.2 6 0.8 9.4 6 1.3* 5.0 6 0.7 11.2 6 2.6*
Data are means 6 SD unless otherwise indicated. rKW/BW, right kidney weight/ body weight; SBP, systolic blood pressure; Tg, EC-PKCb2Tg
mice. *P , 0.05 vs. nondiabetic WT mice.
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2972 DIABETES, VOL. 61, NOVEMBER 2012 diabetes.diabetesjournals.orgFIG. 3. Functional and histological examinations of diabetic EC-PKCb2Tg and WT mice. A: Albuminuria in mice with STZ-induced diabetes (DM),
nondiabetic mice (NDM), WT mice, and EC-PKCb2Tg mice is shown. n = 6 in nondiabetic WT and diabetic WT mice; n = 7 in nondiabetic transgenic
(Tg) and diabetic transgenic mice. **P < 0.001 vs. nondiabetic WT mice. †P < 0.05 vs. diabetic WT mice. B: Representative views of GBM in each
group of mice and quantiﬁcation of GBM thickness in each group of mice. Bar = 1 mm. n = 6 in nondiabetic WT and diabetic WT mice; n =7i n
nondiabetic transgenic and diabetic transgenic mice. *P < 0.05 vs. nondiabetic WT mice. †P < 0.05 vs. diabetic WT mice. C: Representative light
microscopic appearance of glomeruli (periodic acid–Schiff [PAS] and periodic acid–methenamine-silver [PAM] staining), immunohistochemistry of
Col4 and ﬁbronectin, and morphometric analysis of periodic acid–methenamine-silver–, Col4-, and ﬁbronectin-positive staining area. The glo-
merular periodic acid–methenamine-silver–, Col4-, and ﬁbronectin-positive staining area was measured. Bar = 50 mm. n = 6 in nondiabetic WT and
diabetic WT mice; n = 7 in nondiabetic transgenic and diabetic transgenic mice. *P < 0.05 vs. nondiabetic WT mice. †P < 0.05 vs. diabetic WT mice.
Magniﬁcation 3400. D: Immunostaining for PAI-1 in each group of mice and analysis of glomerular expression of PAI-1. Bar = 50 mm. n =6i n
nondiabetic WT and diabetic WT mice; n = 7 in nondiabetic transgenic and diabetic transgenic mice. *P < 0.05 vs. nondiabetic WT mice. †P < 0.05
vs. diabetic WT mice. Magniﬁcation 3400. One of three independently performed experiments is shown. Results are expressed as means 6 SD. For
all the studies above, comparisons were made between groups using either two-sample and paired t tests for two-way comparisons or one-way
ANOVA for multiple groups to establish statistically signiﬁcant differences. (A high-quality digital representation of this ﬁgure is available in the
online issue.)
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diabetes.diabetesjournals.org DIABETES, VOL. 61, NOVEMBER 2012 2973FIG. 4. Effect of exendin-4 (Ex-4) treatment in EC-PKCb2Tg mice. A: Urinary cAMP excretions in each group are shown: mice with STZ-induced diabetes
(DM), nondiabetic mice (NDM), WT mice, and EC-PKCb2Tg mice. n = 6 in nondiabetic WT plus vehicle, nondiabetic WT plus exendin-4, diabetic WT plus
vehicle, diabetic WT plus exendin-4, nondiabetic transgenic (Tg) plus exendin-4, and diabetic transgenic plus exendin-4; n = 7 in nondiabetic transgenic
plus vehicle and diabetic transgenic plus vehicle. *P < 0.05 vs. WT/nondiabetic/exendin-4
2;¶ P < 0.05 vs. WT/nondiabetic/exendin-4
+. B: Albuminuria in
each test group is shown. n = 6 in nondiabetic WT plus vehicle, nondiabetic WT plus exendin-4, diabetic WT plus vehicle, diabetic WT plus exendin-4,
nondiabetic transgenic plus exendin-4, and diabetic transgenic plus exendin-4; n = 7 in nondiabetic transgenic plus vehicle and diabetic transgenic plus
vehicle. *P < 0.05 vs. WT/nondiabetic/exendin-4
2; †P < 0.05 vs. WT/diabetic/exendin-4
2; ‡P < 0.05 vs. transgenic/diabetic/exendin-4
2. C: Representative
light microscopic appearance of glomeruli periodic acid–Schiff (PAS) and periodic acid–methenamine-silver (PAM) staining. Bar = 50 mm. n = 6 in non-
diabetic WT plus vehicle, nondiabetic WT plus exendin-4, diabetic WT plus vehicle, diabetic WT plus exendin-4, nondiabetic transgenic plus exendin-4, and
diabetic transgenic plus exendin-4; n = 7 in nondiabetic transgenic plus vehicle and diabetic transgenic plus vehicle. Magniﬁcation 3400.
D: Immunostaining for PAI-1 in each group of mice is shown. Bar = 50 mm. n = 6 in nondiabetic WT plus vehicle, nondiabetic WT plus exendin-4, diabetic WT
plus vehicle, diabetic WT plus exendin-4, nondiabetic transgenic plus exendin-4, and diabetic transgenic plus exendin-4; n = 7 in nondiabetic transgenic
plus vehicle and diabetic transgenic plus vehicle. Magniﬁcation 3400. One of three independently performed experiments is shown. Results are expressed
as means 6 SD. Comparisons were made between groups using either two-sample and paired t tests for two-way comparisons or one-way ANOVA for
multiple groups to establish statistically signiﬁcant differences. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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2974 DIABETES, VOL. 61, NOVEMBER 2012 diabetes.diabetesjournals.orgFIG. 5. Exendin-4 (Ex-4) decreased effect of Ang II on Erk1/2/PAI-1 signaling. A: Immunoblots of phospho–c-Raf (p-c-Raf)(Ser259), phospho–
c-Raf(Ser338), and phospho-Erk1/2 (p-Erk1/2) in RGECs stimulated with Ang II in the presence or absence of PD98059, SB203580, exendin-4,
or H89. **P < 0.001 vs. Ang II
2/PD98059
2/SB203580
2/exendin-4
2/H89
2; †P < 0.05 vs. Ang II
2/PD98059
2/SB203580
2/exendin-4
+/H89
2; ‡P < 0.05,
‡‡P < 0.001 vs. Ang II
+/PD98059
2/SB203580
2/exendin-4
2/H89
2;¶ P < 0.05 vs. Ang II
+/PD98059
2/SB203580
2/exendin-4
+/H89
2. B: Immunoblots of
phospho–c-Raf(Ser259), phospho–c-Raf(Ser338), and phospho-Erk1/2 in RGECs stimulated with Ang II (10 nmol/L) in the presence or absence of
exendin-4 or MDL12330A. *P < 0.05, **P < 0.001 vs. Ang II
2/exendin-4
2/MDL12330A
2; †P < 0.05 vs. Ang II
2/exendin-4
+/MDL12330A
2; ‡P < 0.05
vs. Ang II
+/exendin-4
2/MDL12330
2;¶ P < 0.05 vs. Ang II
+/exendin-4
+/MDL12330
2. One of three independently performed experiments is shown.
Comparisons were made between groups using either two-sample and paired t tests for two-way comparisons or one-way ANOVA for multiple
groups to establish statistically signiﬁcant differences. Results are expressed as means 6 SD. AU, arbitrary units.
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diabetes.diabetesjournals.org DIABETES, VOL. 61, NOVEMBER 2012 2975FIG. 6. Effect of PKC activation (PMA), knockdown, or blocking of GLP-1R on exendin-4 (Ex-4)-stimulated inhibition of Ang II on phospho–c-Raf
(p-c-Raf)(Ser338), phospho-Erk1/2 (p-Erk1/2), and PAI-1 activity in RGECs. A: Immunoblots of phospho–c-Raf(Ser259), phospho–c-Raf(Ser338),
and phospho-Erk1/2 in RGECs stimulated with PMA (100 nmol/L) in the presence or absence of exendin-4 are shown. **P < 0.001 vs. PMA
2/
exendin-4
2 and †P < 0.05 vs. PMA
+/exendin-4
2. B: Immunoblots of phospho–c-Raf(Ser338) and phospho-Erk1/2 in RGECs stimulated with PMA in
the presence or absence of GFX or RBX. *P < 0.05 vs. PMA
2/GFX
2/RBX
2; †P < 0.05 vs. PMA
+/GFX
2/RBX
2. C: Immunoblots of phospho–c-Raf
(Ser338) and phospho-Erk1/2 in RGECs stimulated with Ang II in the presence or absence of GFX or RBX. *P < 0.05 vs. Ang II
2/GFX
2/RBX
2; †P <
0.05 vs. Ang II
+/GFX
2/RBX
2. D: Immunoblots of phospho–c-Raf(Ser259), phospho–c-Raf(Ser338), and phospho-Erk1/2 in RGECs transfected with
small interfering GLP-1R or small interfering control, stimulated with Ang II in the presence or absence of exendin-4. **P < 0.001 vs. small in-
terfering control/Ang II
2/exendin-4
2; †P < 0.05 vs. siControl/Ang II
2/exendin-4
+; ‡P < 0.05 vs. siControl/Ang II
+/exendin-4
2;¶ P < 0.05 vs.
siControl/Ang II
+/exendin-4
+. E: Immunoblots of phospho–c-Raf(Ser259), phospho–c-Raf(Ser338), and phospho-Erk1/2 in RGECs stimulated with
Ang II in the presence or absence of exendin-4 or exendin-3(9-39) [Ex-3(9-39)] are shown. **P < 0.001 vs. Ang II
2/exendin-4
2/exendin-3(9-39)
2;
†P < 0.05 vs. Ang II
2/exendin-4
+/exendin-3(9-39)
2; ‡P < 0.05 vs. Ang II
+/exendin-4
2/exendin-3(9-39)
2;¶ P < 0.05 vs. Ang II
+/exendin-4
+/exendin-3
(9-39)
2. One of three independently performed experiments is shown. Comparisons were made between groups using either two-sample and paired
t tests for two-way comparisons or one-way ANOVA for multiple groups to establish statistically signiﬁcant differences. Results are expressed as
means 6 SD. AU, arbitrary units.
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2976 DIABETES, VOL. 61, NOVEMBER 2012 diabetes.diabetesjournals.orgFIG. 7. Exendin-4 (Ex-4) decreased angiotensin II or diabetes-induced increases of phospho–c-Raf (p-c-Raf)(Ser338) in the glomeruli and renal
cortex. A: Immunoblots of phospho–c-Raf(Ser259), phospho–c-Raf(Ser338), and phospho-Erk1/2 (p-Erk1/2) in the glomeruli. Exendin-4 (1.0
nmol/kg) or diluents were administrated intraperitoneally to mice. After 2-h administration of exendin-4, Ang II (100 ng/kg/3 mL/min) or saline
was infused through the jugular vein. After 3-h continuous infusion, glomeruli were corrected. n =3 –5. Tg, transgenic. *P < 0.05 vs. WT/Ang II
2/
exendin-4
2; †P < 0.05 vs. WT/Ang II
+/exendin-4
2; ‡P < 0.05 vs. transgenic/Ang II
2/exendin-4
2;¶ P < 0.05 vs. WT/Ang II
+/exendin-4
2;# P < 0.05
vs. transgenic/Ang II
+/exendin-4
2. B: Immunoblots of phospho–c-Raf(Ser259), phospho–c-Raf(Ser338), and phospho-Erk1/2 in the renal cortex.
n = 6 in nondiabetic WT plus vehicle, nondiabetic WT plus exendin-4, diabetic WT plus vehicle, diabetic WT plus exendin-4, nondiabetic
transgenic plus exendin-4, and diabetic transgenic plus exendin-4; n = 7 in nondiabetic transgenic plus vehicle and diabetic transgenic plus
vehicle. DM, mice with STZ-induced diabetes; NDM, nondiabetic mice. *P < 0.05 vs. WT/nondiabetic/exendin-4
2; †P < 0.05 vs. WT/diabetic/
exendin-4
2; ‡P < 0.05 vs. transgenic/diabetic/exendin-4
2. One of three independently performed experiments is shown. Comparisons were
made between groups using either two-sample and paired t tests for two-way comparisons or one-way ANOVA for multiple groups to establish
statistically signiﬁcant differences. Results are expressed as means 6 SD. C: Schematic diagram of the inhibitory effects of PKCb2o nt h e
protective action of GLP-1 signaling against the effects of Ang II–mediated glomerular pathology. AU, arbitrary units; ECM, extracellular
matrix.
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c-Raf(Ser259). The reduction of c-Raf phosphorylation at
Ser338 by GLP-1 caused decreases in phospho-Erk1/2 and
PAI-1 in the renal glomeruli.
Diabetes of long duration also inhibited GLP-1–protective
action by decreasing GLP-1R via increases in ubiquitination
of GLP-1R. However, Zhou et al. (27) reported that high-
glucose conditions did not decrease GLP-1R protein ex-
pression or increase its ubiquitination in the islet cells after
24 h. Further, Kodera et al. (9) reported that GLP-1R
was not decreased in the glomeruli of rats with STZ-induced
diabetes after several weeks of disease. However,
Park et al. (8) reported that GLP-1R was decreased in the
glomeruli of db/db mice and exendin-4 treatment amelio-
rated this decrease. These differences are likely due to
using different cell types and mice strains and length of
diabetes.
Thus, our results suggest that PKCb activation induced
by hyperglycemia can inhibit GLP-1–protective action and
enhance inﬂammatory effects on the endothelium by at
least two signaling pathways. First, our results expand on
previous ﬁndings and show that PKCb activation can en-
hance Ang II effect by phosphorylating c-Raf at Ser338 to
activate phospho-Erk1/2 and cause increased production
of PAI-1 (28). Second, we found that PKC activation can
also inhibit the protective actions of GLP-1 by reducing the
expression of its receptors in the endothelial cells. One
potential mediator of Ang II adverse effect in endothelial
cells is the induction of PAI-1 (7), which may impair ﬁ-
brinolysis and promote increased extracellular matrix
(29,30).
Our study identiﬁes the biochemical mechanisms by
which PKC activation can increase the actions of Ang II.
The results demonstrate that PKC activation, especially
PKCb, increased phospho–c-Raf(Ser338), which leads to
the activation of phospho-Erk1/2. This activation is selec-
tive for PKCb isoform, since RBX, a PKCb isoform–speciﬁc
selective inhibitor, inhibited phospho–c-Raf(Ser338). In
addition, infusion of Ang II in EC-PKCb2Tg mice increased
phospho–c-Raf(Ser338) to a greater extent than in WT
mice both in vivo and in endothelial cells. In parallel with
changes in phospho–c-Raf(Ser338), EC-PKCb2Tg mice
exhibited greater expression of PAI-1 than did controls
after Ang II infusion. It is interesting to note, however, that
endothelial dysfunction induced by the overexpression of
PCKb alone, speciﬁcally in the endothelial cells, without the
presence of diabetes did not exhibit signiﬁcant pathology as
measured by mesangial matrix expression and PAI-1. Thus,
endothelial dysfunction alone without diabetes will only
induce minimal albuminuria and extracellular matrix pro-
duction. Studies using long-duration treatment of Ang II
will be needed to correlate changes in phospho–c-Raf and
glomerular pathology.
The second new ﬁnding shows that diabetes and hy-
perglycemia via PKCb activation will blunt the protective
actions of GLP-1 by decreasing GLP-1R protein expression
in the endothelium. The reduction in GLP-1R is manifested
by a decrease in urinary cAMP with infusion of exendin-4
and less reduction in phospho–c-Raf(Ser338)/phospho-
Erk1/2 in the glomeruli of EC-PKCb2Tg mice. However, even
with the reduction in GLP-1R, treatment with exendin-4
in vivo was still partially effective to reduce glomerular
pathology of both diabetic WT and EC-PKCb2Tg mice. It is
surprising that exendin-4 still had positive effects on the
glomerular pathology, although it did not increase urinary
cAMP signiﬁcantly. This could be due to the difﬁculty of
measuring cAMP as a result of degradation in urine that
took 24 h to collect and the dilution of samples by the
increases of urine volume induced by diabetes. It is also
possible that the beneﬁcial effects of exendin-4 could
be partially mediated via cAMP-independent pathways.
All of the protective actions of exendin-4 occurred with-
out changes in glucose, insulin level, blood pressure, and
body weight.
Thus, our study has identiﬁed mechanisms by which
GLP-1 can induce protective actions on the glomerular
endothelial cells by inhibiting the signaling pathway of Ang
II at phospho–c-Raf(Ser338) via phospho–c-Raf(Ser259).
Further, we have demonstrated, in vivo and in vitro, that
hyperglycemia can activate PKCb isoforms, which en-
hance Ang II toxic effect in glomerular endothelial cells.
These studies suggest that effective therapeutic agents
could be designed to enhance GLP-1R on the endothelium,
which may prevent glomerular endothelial dysfunction
and slow the progression of diabetic nephropathy.
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